Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro

Current Eye Research

Volumn 15, Issue 11, 1996, Pages 1112-1116

  Schmidt, J F ^a   Loeffler, K U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Aclacinomycin A; Aclarubicin; Antiproliferative effect; Cell culture; Pig; Proliferative vitreoretinopathy; Retinal pigment epithelium

Indexed keywords

ACLARUBICIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SWINE; VITREORETINOPATHY;

EID: 0029854131     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.3109/02713689608995142     Document Type: Article

References (32)

1. Cleary, P. E. and Ryan, S. J. (1981) Mechanisms in traction retinal detachment. Dev. Ophthalmol. 2, 328-333.
2. Freeman, H. M. (1973) Recent advances in vitreous surgery. Invest. Ophthalmol. Vis. Sci. 12, 549-551.
3. Machemer, R. (1977) Massive periretinal proliferation: a logical approach to therapy. Trans. Am. Ophthalmol. Soc. 75, 556-586.
4. Shafer, D. M. (1974) Total vitrectomy for massive retinal contracture. In Retina Congress (Eds. Pruett, R. C. and Regan, C. D.). P. 703. Appleton-Century-Crofts, New York.
5. Hilton, G., Machemer, R., Okun, E., Schepens, C. and Schwarz, A. (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology, 90, 121-125.
6. Machemer, R. (1978) Pathogenesis and classification of massive periretinal proliferation. Br. J. Ophthalmol. 62, 737-747.
7. Kampik, A., Kenyon, K. R., Michels, R. G., Green, W. R. and de la Cruz, Z. C. (1981) Epiretinal and vitreous membranes: comparative study of 56 cases. Arch. Ophthalmol. 99, 445-454.
8. Wiedemann, P. and Heimann, K. (1986) Proliferative vitreoretinopathy-pathogenesis and treatment with antiproliferative drugs. Klin. Mbl. Augenheilk. 188, 559-562.
9. Machemer, R., Sugita, G. and Tano, Y. (1979) Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc. 77, 171-180.
10. Blumenkranz, M. S., Ophir, A., Claflin, A. J. and Hajek, A. (1982) Fluorouracil for the treatment of massive periretinal proliferation. Am. J. Ophthalmol. 94, 458-467.
11. Wiedemann, P., Lemmen, K., Schmiedl, R. and Heimann, K. (1987) Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am. J. Ophthalmol. 104, 10-14.
12. Wiedemann, P., Sorgente, N., Bekhor, C., Patterson, R., Tran, T. and Ryan, S. J. (1985) Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 26, 719-725.
13. Santana, M., Wiedemann, P., Kirmani, M., Minckler, D. S., Patterson, R., Sorgente, N. and Ryan, R. (1984) Daunomycin in the treatment of experimental vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefe's Arch. Clin. Exp. Ophthalmol. 221, 210-213.
14. Maral, R. J. and Jouanne, M. (1981) Toxicology of daunorubicin in animals and man. Cancer Treatment Reports, 65 (Suppl. 4), 9-18.
15. Wiedemann, P., Kirmani, M., Santana, M., Sorgente, N. and Ryan, S. J. (1983) Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefe's Arch. Clin. Exp. Ophthalmol. 220, 233-235.
16. Westendorf, J., Marquardt, H. and Marquardt, H. (1982) Anthracycline antitumour antibiotics: their carcinogenicity and their mutagenicity. In Anthracycline Antibiotics in Cancer Therapy (Eds. Muggia, F. M., Young, C. W. and Carter, S.). Pp. 30-49. Martinus Nijhoff, The Hague.
17. Westendorf, J., Marquardt, H. and Marquardt, H. (1984) Structure-activity relationship of anthracycline-induced genotoxicity. Cancer Res. 44, 5599-5604.
18. Suzuki, H., Kawashima, K. and Yamada, K. (1979) Aclacinomycin A, a new anti-leucemic agent. Lancet, 2, 870-871.
19. Umezawa, K., Sawamura, M., Matsushima, T. and Sugimura, T. (1978) Mutagenicity of aclacinomycin A and daunomycin derivatives. Cancer Res. 32, 1782-1784.
20. Westendorf, J., Marquardt, H., Ketkar, M. B., Mohr, U. and Marquardt, H. (1983) Tumorigenicity in vivo and induction mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests. Cancer Res. 43, 5248-5251.
21. Steinhorst, U. H., Chen, E. P., Hatchell, D. L., Samsa, G. P., Saloupis, P. T., Westendorf, J. and Machemer, R. (1993) Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 34, 1753-1760.
22. Flood, M. T., Gouras, P. and Kjeldbye, H. (1980) Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest. Ophthalmol. Vis. Sci. 19, 1309-1320.
23. Kirmani, M., Santana, M., Sorgente, N., Wiedemann, P. and Ryan, S. J. (1983) Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina, 3, 269-272.
24. Kirmani, M., Santana, M., Sorgente, N., Wiedemann, P. and Ryan, S. J. (1983) Drug treatment of MPP. (Abstract). Invest. Ophthalmol. Vis. Sci. 24 (Suppl.), 241.
25. Weller, M., Heimann, K. and Wiedemann, P. (1987) Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro. Graefe's Arch. Clin. Exp. Ophthalmol. 225, 235-238.
26. Wiedemann, P., Evans, P. Y., Wiedemann, R., Meyer-Schwickerath, R. and Heimann, K. (1989) A fluorescein angiographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin. Int. Ophthalmol. 13, 211-216.
27. Acton, E. M. (1980) N-alkylation of anthracyclines. In Anthracyclines: Current Status and New Developments (Eds. Crooke, S. T. and Reich, S. D.). Pp. 15-25. Academic, New York.
28. Zenebergh, A., Baurain, R. and Trouet, A. (1982) Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Cancer Chemother. Pharmacol. 8, 243-249.
29. Bachur, N. R., Steele, M., Meriwether, W. D. and Hildebrandt, R. C. (1976) Cellular pharmacodynamics of several anthracycline antibiotics. J. Med. Chem. 19, 651.
30. Wheeler, C. S. and Kessel, D. (1980) Influx of anthracyclines by murine leucemia cells as a function of drug lipophilicity and membrane fluidity. Pharmacologist, 22, 291.
31. Tone, H., Nishida, H., Takeuchi, T., and Umezawa, H. (1985) Experimental studies on aclacinomycin. Drugs Exp. Clin. Res. 11, 9-15.
32. Yamaki, H., Suzuki, H., Nishimura, T. and Tanaka, M. (1978) Mechanism of action of aclacinomycin A1: the effect on macromolecular synthesis. J. Antibiot. 31, 1149.